State of the Art Molecular Pharmacology, Pathogenesis and Epigenetics of 3 Major Cancers: Lung Cancer, Ovarian Cancer, and Gliomas

2021 ◽  
Vol 14 (6) ◽  
pp. 1003-1003
Author(s):  
Fotios Sampsonas
Keyword(s):  
Lung Cancer ◽  
Ovarian Cancer ◽  
State Of The Art ◽  
Molecular Pharmacology

Perbandingan CART dan Random Forest untuk Deteksi Kanker berbasis Klasifikasi Data Microarray

2020 ◽  
Vol 4 (5) ◽  
pp. 805-812
Author(s):  
Riska Chairunisa ◽  
Adiwijaya ◽  
Widi Astuti
Keyword(s):  
Breast Cancer ◽  
Lung Cancer ◽  
Ovarian Cancer ◽  
Random Forest ◽  
Classification And Regression Tree ◽  
Classification Method ◽  
Discrete Wavelet ◽  
Prostate Tumors ◽  
Cancer Data ◽  
Colon Tumors

Cancer is one of the deadliest diseases in the world with a mortality rate of 57,3% in 2018 in Asia. Therefore, early diagnosis is needed to avoid an increase in mortality caused by cancer. As machine learning develops, cancer gene data can be processed using microarrays for early detection of cancer outbreaks. But the problem that microarray has is the number of attributes that are so numerous that it is necessary to do dimensional reduction. To overcome these problems, this study used dimensions reduction Discrete Wavelet Transform (DWT) with Classification and Regression Tree (CART) and Random Forest (RF) as classification method. The purpose of using these two classification methods is to find out which classification method produces the best performance when combined with the DWT dimension reduction. This research use five microarray data, namely Colon Tumors, Breast Cancer, Lung Cancer, Prostate Tumors and Ovarian Cancer from Kent-Ridge Biomedical Dataset. The best accuracy obtained in this study for breast cancer data were 76,92% with CART-DWT, Colon Tumors 90,1% with RF-DWT, lung cancer 100% with RF-DWT, prostate tumors 95,49% with RF-DWT, and ovarian cancer 100% with RF-DWT. From these results it can be concluded that RF-DWT is better than CART-DWT.  

scholarly journals The Role of Surgery in Lung Cancer Treatment: Present Indications and Future Perspectives—State of the Art

Cancers ◽  
2021 ◽  
Vol 13 (15) ◽  
pp. 3711
Author(s):  
François Montagne ◽  
Florian Guisier ◽  
Nicolas Venissac ◽  
Jean-Marc Baste
Keyword(s):  
Lung Cancer ◽  
Residual Disease ◽  
State Of The Art ◽  
Locally Advanced ◽  
Small Cell Lung ◽  
Lung Cancers ◽  
Screening Programs ◽  
Systemic Therapies

Non-small cell lung cancers (NSCLC) are different today, due to the increased use of screening programs and of innovative systemic therapies, leading to the diagnosis of earlier and pre-invasive tumors, and of more advanced and controlled metastatic tumors. Surgery for NSCLC remains the cornerstone treatment when it can be performed. The role of surgery and surgeons has also evolved because surgeons not only perform the initial curative lung cancer resection but they also accompany and follow-up patients from pre-operative rehabilitation, to treatment for recurrences. Surgery is personalized, according to cancer characteristics, including cancer extensions, from pre-invasive and local tumors to locally advanced, metastatic disease, or residual disease after medical treatment, anticipating recurrences, and patients’ characteristics. Surgical management is constantly evolving to offer the best oncologic resection adapted to each NSCLC stage. Today, NSCLC can be considered as a chronic disease and surgery is a valuable tool for the diagnosis and treatment of recurrences, and in palliative conditions to relieve dyspnea and improve patients’ comfort.

e-Nose Technology: The State of the Art on Lung Cancer Diagnosis

2019 ◽  
pp. 121-129 ◽  
Author(s):  
P.F. Crucitti ◽  
Filippo Longo ◽  
Raffaele Rocco ◽  
Gaetano Rocco
Keyword(s):  
Lung Cancer ◽  
Cancer Diagnosis ◽  
State Of The Art ◽  
The State ◽  
Lung Cancer Diagnosis

scholarly journals Anticancer Applications and Pharmacological Properties of Piperidine and Piperine: A Comprehensive Review on Molecular Mechanisms and Therapeutic Perspectives

2022 ◽  
Vol 12 ◽  
Author(s):  
Sicon Mitra ◽  
Uttpal Anand ◽  
Niraj Kumar Jha ◽  
Mahipal S. Shekhawat ◽  
Suchismita Chatterjee Saha ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prostate Cancer ◽  
Lung Cancer ◽  
Ovarian Cancer ◽  
Molecular Mechanisms ◽  
Therapeutic Potential ◽  
Black Pepper ◽  
Piper Nigrum ◽  
Molecular Formula ◽  
Cycle Arrest

Piperine and piperidine are the two major alkaloids extracted from black pepper (Piper nigrum); piperidine is a heterocyclic moiety that has the molecular formula (CH2)5NH. Over the years, many therapeutic properties including anticancer potential of these two compounds have been observed. Piperine has therapeutic potential against cancers such as breast cancer, ovarian cancer, gastric cancer, gliomal cancer, lung cancer, oral squamous, chronic pancreatitis, prostate cancer, rectal cancer, cervical cancer, and leukemia. Whereas, piperidine acts as a potential clinical agent against cancers, such as breast cancer, prostate cancer, colon cancer, lung cancer, and ovarian cancer, when treated alone or in combination with some novel drugs. Several crucial signalling pathways essential for the establishment of cancers such as STAT-3, NF-κB, PI3k/Aκt, JNK/p38-MAPK, TGF-ß/SMAD, Smac/DIABLO, p-IκB etc., are regulated by these two phytochemicals. Both of these phytochemicals lead to inhibition of cell migration and help in cell cycle arrest to inhibit survivability of cancer cells. The current review highlights the pharmaceutical relevance of both piperine and piperidine against different types of cancers.

scholarly journals Remote recurrence from ovarian cancer mimicking lung cancer

2022 ◽  
Author(s):  
Sho Yamada ◽  
Akimasa Sekine ◽  
Takashi Ogura
Keyword(s):  
Lung Cancer ◽  
Ovarian Cancer

scholarly journals State-of-the-art considerations in small cell lung cancer brain metastases

Oncotarget ◽  
2017 ◽  
Vol 8 (41) ◽  
pp. 71223-71233 ◽  
Author(s):  
Rimas V. Lukas ◽  
Vinai Gondi ◽  
David O. Kamson ◽  
Priya Kumthekar ◽  
Ravi Salgia
Keyword(s):  
Lung Cancer ◽  
Brain Metastases ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
State Of The Art ◽  
Small Cell ◽  
Small Cell Lung

scholarly journals Intraoperative Molecular Imaging in Lung Cancer: The State of the Art and the Future

2018 ◽  
Vol 26 (2) ◽  
pp. 338-341 ◽  
Author(s):  
Stephan Rogalla ◽  
Sebastiaan C.M. Joosten ◽  
Israt S. Alam ◽  
Sanjiv S. Gambhir ◽  
Ophir Vermesh
Keyword(s):  
Lung Cancer ◽  
Molecular Imaging ◽  
State Of The Art ◽  
The State ◽  
The Future

scholarly journals Pharmacogenomics, Pharmacokinetics and Circulating Proteins As Biomarkers for Bevacizumab Treatment Optimization in Patients with Cancer: A Review

2020 ◽  
Vol 10 (3) ◽  
pp. 79 ◽  
Author(s):  
Apostolos Papachristos ◽  
Gregory B. Sivolapenko
Keyword(s):  
Colorectal Cancer ◽  
Lung Cancer ◽  
Ovarian Cancer ◽  
Monoclonal Antibody ◽  
Therapeutic Drug ◽  
Clinical Use ◽  
Treatment Optimization ◽  
Patients With Cancer ◽  
Research Fields ◽  
Bevacizumab Treatment

Bevacizumab is a monoclonal antibody that targets VEGF-A and inhibits tumor angiogenesis. Bevacizumab is approved for the treatment of various cancer, including metastatic colorectal cancer (mCRC), ovarian cancer, lung cancer, and others. Thus, it is widely used in oncology, but contrary to other therapeutic classes, there is still a lack of validating predictive factors for treatment outcomes with these agents. In recent years, the research for factors predictive of anti-VEGF treatments and especially bevacizumab response has been one of the most competitive translational research fields. Herein, we review and present the available literature of the clinical use of biomarkers, pharmacogenomics (PG), and therapeutic drug monitoring (TDM) approaches that can be used for the optimization of bevacizumab use in the era of precision medicine.

Sign in / Sign up

Export Citation Format

Share Document